Annexon, Inc.
A clinical-stage biopharmaceutical company developing therapies that target the complement system, the part of the immune system that helps clear damaged cells and defend against infection. Its lead programs focus on treating autoimmune and inflammatory diseases of the nervous system and eye. The company was founded in 2011 and is headquartered in Brisbane, California.
Bought 8.39M
Bought 300.0K
Granted 300.9K · Bought 60.0K · Sold 24.9K
Granted 219.7K · Sold 94.8K
Granted 187.3K · Sold 26.2K
Granted 146.5K · Sold 16.7K
Granted 190.8K · Sold 35.2K
Granted 140.2K · Sold 16.6K
Bought 78.4K
Bought 33.0K
Granted 21.9K
Granted 12.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Satter Muneer ADirector · 9 transactions | — | 28.98M | — | 8.39M | — |
| BCIP Life Sciences Associates, LP +3 co-filers10% owner · 1 transaction | — | 5.40Mas of May 2023 | — | 300.0K | — |
| Love DouglasPRESIDENT AND CEO, Director · 12 transactions | — | 351.6Kas of Feb 2025 | 300.9K | 60.0K | 24.9K |
| Yednock TedEVP & CHIEF INNOVATION OFFICER · 25 transactions | — | 184.8K | 219.7K | — | 94.8K |
| Overdorf MichaelEVP & CHIEF BUSINESS OFFICER · 17 transactions | — | 182.6K | 187.3K | — | 26.2K |
| Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER · 6 transactions | — | 180.1K | 146.5K | — | 16.7K |
| Lew JenniferEVP & CHIEF FINANCIAL OFFICER · 19 transactions | +3003.6% | 170.7K | 190.8K | — | 35.2K |
| Dananberg JamieCHIEF MEDICAL OFFICER · 6 transactions | — | 123.6K | 140.2K | — | 16.6K |
| Carson William H.Director · 18 transactions | — | 78.4K | — | 78.4K | — |
| Choi JungDirector · 1 transaction | — | 33.0K | — | 33.0K | — |
| Mattheakis LarryEVP & Chief Scientific Officer · 3 transactions | — | 17.2Kas of Jul 2022 | 21.9K | — | — |
| Keswani SanjayEVP & Chief Medical Officer · 1 transaction | — | 12.5Kas of Feb 2022 | 12.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +8.64M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.